Biomarker discovery analysis: Alterations in p14, p16, p53, and BAP1 expression in nevi, cutaneous melanoma, and metastatic melanoma

Pigment Cell Melanoma Res. 2019 May;32(3):474-478. doi: 10.1111/pcmr.12768. Epub 2019 Feb 10.
No abstract available

Keywords: BAP1; biomarker; melanoma; p14ARF; p16; p53; prognosis.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers, Tumor / metabolism
  • Case-Control Studies
  • Cyclin-Dependent Kinase Inhibitor p16 / metabolism*
  • Female
  • Follow-Up Studies
  • Genes, Tumor Suppressor
  • Humans
  • Lymphatic Metastasis
  • Male
  • Melanoma / metabolism
  • Melanoma / pathology*
  • Melanoma, Cutaneous Malignant
  • Middle Aged
  • Nevus, Pigmented / metabolism
  • Nevus, Pigmented / pathology*
  • Oncogene Proteins / metabolism*
  • Prognosis
  • Prospective Studies
  • Skin Neoplasms / metabolism
  • Skin Neoplasms / pathology
  • Skin Neoplasms / secondary*
  • Tumor Suppressor Protein p53 / metabolism*
  • Tumor Suppressor Proteins / metabolism*
  • Ubiquitin Thiolesterase / metabolism*

Substances

  • BAP1 protein, human
  • Biomarkers, Tumor
  • CDK2AP2 protein, human
  • CDKN2A protein, human
  • Cyclin-Dependent Kinase Inhibitor p16
  • Oncogene Proteins
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • Tumor Suppressor Proteins
  • Ubiquitin Thiolesterase